Patent ID: 11912760
Assignee: PHAROSGEN CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 2:
3. A doppel-targeting molecule that binds to doppel, wherein the doppel-targeting molecule is selected from a doppel-binding murine antibody produced by a hybridoma cell line clone selected from:
(i) Hybridoma cell line clone 2B6, deposited on Sep. 29, 2020 with Korean Cell Line Research Foundation as hPrnd #2B6 under Accession Number KCLRF-BP-00490;
(ii) Hybridoma cell line clone 2A8, deposited on Sep. 29, 2020 with Korean Cell Line Research Foundation as mPrnd #2A8 under Accession Number KCLRF-BP-00489;
(iii) Hybridoma cell line clone 7A11, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #7A11 under Accession Number KCLRF-BP-00498;
(iv) Hybridoma cell line clone 7G3, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #7G3 under Accession Number KCLRF-BP-00500;
(v) Hybridoma cell line clone 2E9, deposited on Sep. 29, 2020 with Korean Cell Line Research Foundation as hPrnd #2E9 under Accession Number KCLRF-BP-00493;
(vi) Hybridoma cell line clone 4E3, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #4E3 under Accession Number KCLRF-BP-00495;
(vii) Hybridoma cell line clone 4H7, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #4H7 under Accession Number KCLRF-BP-00496;
(viii) Hybridoma cell line clone 2C10, deposited on Sep. 29, 2020 with Korean Cell Line Research Foundation as hPrnd #2C10 under Accession Number KCLRF-BP-00491;
(ix) Hybridoma cell line clone 2C12, deposited on Sep. 29, 2020 with Korean Cell Line Research Foundation as hPrnd #2C12 under Accession Number KCLRF-BP-00492;
(x) Hybridoma cell line clone 5D3, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #5D3 under Accession Number KCLRF-BP-00497;
(xi) Hybridoma cell line clone 4D5, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #4D5 under Accession Number KCLRF-BP-00494; and
(xii) Hybridoma cell line clone 7D7, deposited on Oct. 19, 2020 with Korean Cell Line Research Foundation as hPrnd #7D7 under Accession Number KCLRF-BP-00499,
and doppel-binding fragments thereof.